Last reviewed · How we verify
Methylrosaniline Chloride (GENTIAN VIOLET)
At a glance
| Generic name | GENTIAN VIOLET |
|---|---|
| Target | Muscarinic acetylcholine receptor M4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Candidal vulvovaginitis
Common side effects
Key clinical trials
- Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli
- Hidradenitis Suppurativa Wound Care (PHASE2)
- Gentian Violet Treatment for Hidradenitis Suppurativa (PHASE2)
- Accuracy for Predicting Deep Submucosal Invasion
- Antibacterial and Anti-biofilm Activity of Frankincense Extract Against Porphyromonas Gingivalis (PHASE1)
- Investigation of Bacterial Adhesion and Bactericide Effect ex Vivo on Different Implant Restoration Materials (NA)
- Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis (PHASE3)
- A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |